Skip to content
OpenCapital
Get started

Alkermes ALKS Contract Assets

Contract Assets at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$73.68M+85.6%

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerAssetNetCurrent.

The official record: Alkermes’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's contract assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's contract assets?
Alkermes (ALKS) reported contract assets of $0 in Q4 2025.
How has Alkermes's contract assets changed year-over-year?
Alkermes's contract assets decreased by 100.0% year-over-year, from $4.99M to $0.
What is the long-term trend for Alkermes's contract assets?
Over 5 years (2020 to 2025), Alkermes's contract assets has grown at a -100.0% compound annual growth rate (CAGR), from $14.4M to $0.
What does contract assets mean?
Revenue recognized under ASC 606 where the right to payment is conditional on something other than the passage of time — work performed but not yet billable.